AI Article Synopsis

  • A renal transplant patient developed unique anti HLA-DP antibodies before showing signs of chronic humoral rejection.
  • The patient's immune response included not only donor-specific but also non-donor-specific DP antigens, all sharing the same amino-acid sequence.
  • This case suggests that matching epitopes, rather than just HLA antigens, might be more effective in preventing rejection in organ transplants.

Article Abstract

We report the case of a renal transplanted patient, in whom the detection of a unique anti HLA-DP antibody response preceded the development of chronic humoral rejection. In addition to donor-specific anti-DP alloantibodies, the patient displayed reactions against several non-donor-specific DP antigens (NDSA). Interestingly, we found that all the DP molecules recognized by the alloantibodies displayed the same amino-acid sequence suggesting that epitope sharing between unrelated HLA molecules was the mechanism underlying NDSA generation. This case highlights the pathogenicity of anti-DP alloantibodies and suggests that it could be more meaningful to match the epitopes than the HLA antigens for the prevention of rejection.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trim.2008.12.006DOI Listing

Publication Analysis

Top Keywords

chronic humoral
8
humoral rejection
8
epitope sharing
8
anti-dp alloantibodies
8
alloantibodies
5
rejection mediated
4
mediated anti-hla-dp
4
anti-hla-dp alloantibodies
4
alloantibodies insights
4
insights role
4

Similar Publications

Introduction: 58 million people worldwide are chronically infected with hepatitis C virus (HCV) and are at risk of developing cirrhosis and hepatocellular carcinoma (HCC). Direct-acting antivirals are highly effective; however, they are burdened by high costs and the unchanged risk of HCC and reinfection, making prophylactic countermeasures an urgent medical need. HCV high genetic diversity is one of the main obstacles to vaccine development.

View Article and Find Full Text PDF

Background: Helicobacter pylori (H. pylori), a specific bacterium capable of surviving in the acidic environment of the stomach, has been recognized as a group of causative agents of gastric cancer. Therefore, the development of mucosal vaccines against H.

View Article and Find Full Text PDF

Background: Patients with end stage renal disease (ESRD) undergoing hemodialysis are at increased risk for infection and impaired vaccination responses. We analyzed overlap and influencing factors of vaccination responses against severe acute respiratory syndrome corona virus disease 2 (SARS-CoV-2) and Hepatitis B virus (HBV).

Methods: SARS-CoV-2 and HBV vaccination response was assessed in a cohort of German ESRD hemodialysis patients.

View Article and Find Full Text PDF

Introduction: Cystic echinococcosis (CE), a chronic disabling parasitic zoonosis, poses a great threat to public health and livestock production and causes huge economic losses globally. The commercial Quil-A-adjuvanted Eg95 vaccine was empirically effective for CE control; however, it is expensive and has side effects and insufficient immunity.

Purpose: This study aimed to employ a novel adjuvant consisting of a delivery system and an immune potentiator and assess its adjuvanticity to Eg95 antigen, thereby developing a safe and cost-effective novel vaccine against the disease.

View Article and Find Full Text PDF

Background: Chronic graft-versus-host disease (cGVHD) manifests with characteristics of autoimmune disease with organs attacked by pathogenic helper T cells. Recent studies have highlighted the role of T cells in cGVHD pathogenesis. Due to limited understanding of underlying mechanisms, preventing cGVHD after allogenic hematopoietic cell transplantation (HCT) has become a major challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!